Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal dexamethasone disodium phosphate test dose to predict response to Ozurdex in refractory diabetic macular edema
RBR-2bgcvwjPhase 2Not yet recruiting
- Sponsor
- Universidade Federal de Pernambuco
- Start
- Oct 2024
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexamethasone sodium phosphate and ozurdex in diabetic macular edema (DME), sponsored by Universidade Federal de Pernambuco. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
dexamethasone sodium phosphateozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on RBR-2bgcvwj.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2bgcvwj.